Professor Shin Dong-yeop of Seoul National University Hospital Wins Senior Researcher's Award at the Korean Blood Society
Apr 11, 2025
Shin Dong-yeop, a professor of hematologic oncology at Seoul National University Hospital, recently won the Senior Researcher Award at the International Conference of the Korean Blood Society (IKSH2025).
The Senior Researcher Award is given to outstanding researchers who have contributed to the development of hematology in Korea and human health welfare. Among the pure domestic studies conducted in the last two years, the winners are selected by evaluating research papers published in domestic and foreign journals.
As the first author, Professor Shin received the award in January 2024 for publishing a study on the development of osteolytic lesions in multiple myeloma in Haematologica. This is a study that found promising biomarkers for multiple myeloma and suggested the possibility of improving prognosis, and was conducted in cooperation with a team of professors Yoon Sung-soo, Sookmyung Women's University Kim Yong-hwan, and Seoul National University Hwang Dae-hee.
Multiple myeloma is the second most common malignant blood cancer after leukemia and is caused by the differentiation and proliferation of abnormal plasma cells. The main characteristic of this cancer is the melting bone ' osteolytic lesion', which causes fractures and pain, which greatly reduces the quality of life and prognosis of patients. However, the mechanism of development of osteolytic lesions is unknown.
Professor Shin Dong-yeop found that unlike other blood cancers, 'FLT3L' levels were characteristically elevated in bone marrow blood from patients with multiple myeloma. Subsequently, cell and dielectric precise analysis was performed to confirm the association between this substance and osteolytic lesions.
As a result of the study, we identified the mechanism by which FLT3L activates the STAT3-DKK1 pathway and inhibits the WNT signaling pathway involved in bone formation. Furthermore, this mechanism was verified with a large-scale genome dataset, confirming that the risk was higher in hyperdiploidy multiple myeloma.
Professor Shin said, `It is meaningful to receive an award that is insufficient.' `I will take it as an encouragement to devote myself to research on blood cancer treatment and as an opportunity for growth, and further devote myself to research that can convey hope to incurable blood cancer patients.'
Meanwhile, Professor Shin is an expert in hematology who has conducted several studies in the field of cord blood-derived blood stem cells and blood cancer, serving as an international cooperation director and academic director of the Korean Blood Association, and is devoted to the development of hematology in Korea and strengthening global networks.
The Senior Researcher Award is given to outstanding researchers who have contributed to the development of hematology in Korea and human health welfare. Among the pure domestic studies conducted in the last two years, the winners are selected by evaluating research papers published in domestic and foreign journals.
As the first author, Professor Shin received the award in January 2024 for publishing a study on the development of osteolytic lesions in multiple myeloma in Haematologica. This is a study that found promising biomarkers for multiple myeloma and suggested the possibility of improving prognosis, and was conducted in cooperation with a team of professors Yoon Sung-soo, Sookmyung Women's University Kim Yong-hwan, and Seoul National University Hwang Dae-hee.
Multiple myeloma is the second most common malignant blood cancer after leukemia and is caused by the differentiation and proliferation of abnormal plasma cells. The main characteristic of this cancer is the melting bone ' osteolytic lesion', which causes fractures and pain, which greatly reduces the quality of life and prognosis of patients. However, the mechanism of development of osteolytic lesions is unknown.
Professor Shin Dong-yeop found that unlike other blood cancers, 'FLT3L' levels were characteristically elevated in bone marrow blood from patients with multiple myeloma. Subsequently, cell and dielectric precise analysis was performed to confirm the association between this substance and osteolytic lesions.
As a result of the study, we identified the mechanism by which FLT3L activates the STAT3-DKK1 pathway and inhibits the WNT signaling pathway involved in bone formation. Furthermore, this mechanism was verified with a large-scale genome dataset, confirming that the risk was higher in hyperdiploidy multiple myeloma.
Professor Shin said, `It is meaningful to receive an award that is insufficient.' `I will take it as an encouragement to devote myself to research on blood cancer treatment and as an opportunity for growth, and further devote myself to research that can convey hope to incurable blood cancer patients.'
Meanwhile, Professor Shin is an expert in hematology who has conducted several studies in the field of cord blood-derived blood stem cells and blood cancer, serving as an international cooperation director and academic director of the Korean Blood Association, and is devoted to the development of hematology in Korea and strengthening global networks.
|
This article was translated by Naver AI translator.
